Smith & Nephew/£SN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
£SN
Sector
Primary listing
LSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17,349
ISIN
GB0009223206
Website
Smith & Nephew Metrics
BasicAdvanced
£9.4B
30.87
£0.35
0.63
£0.29
2.66%
Price and volume
Market cap
£9.4B
Beta
0.63
52-week high
£12.45
52-week low
£9.11
Average daily volume
2.3M
Dividend rate
£0.29
Financial strength
Current ratio
2.888
Quick ratio
1.215
Long term debt to equity
61.88
Total debt to equity
63.077
Dividend payout ratio (TTM)
79.37%
Interest coverage (TTM)
4.53%
Profitability
EBITDA (TTM)
916.493
Gross margin (TTM)
70.21%
Net profit margin (TTM)
7.09%
Operating margin (TTM)
11.31%
Effective tax rate (TTM)
17.27%
Revenue per employee (TTM)
£244,490
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
7.86%
Valuation
Price to earnings (TTM)
30.871
Price to revenue (TTM)
2.18
Price to book
1.78
Price to tangible book (TTM)
7.76
Price to free cash flow (TTM)
20.902
Free cash flow yield (TTM)
4.78%
Free cash flow per share (TTM)
51.43%
Dividend yield (TTM)
2.66%
Growth
Revenue change (TTM)
4.70%
Earnings per share change (TTM)
56.15%
3-year revenue growth (CAGR)
3.69%
10-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
-7.66%
10-year earnings per share growth (CAGR)
-1.68%
10-year dividend per share growth (CAGR)
2.39%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
Smith & Nephew anticipates an improved profit margin in 2024, targeting at least an 18% trading profit margin compared to 17.5% in 2023, driven by strong demand in orthopaedics and sports medicine segments. (reuters.com)
The company reported a trading profit of $970 million for 2023, meeting market expectations and indicating robust financial health. (reuters.com)
Analysts have given Smith & Nephew a consensus recommendation of 'Moderate Buy,' reflecting positive sentiment towards the company's growth prospects. (marketbeat.com)
The sports medicine division faces challenges in China due to the government's volume-based procurement policy, which is anticipated to be a significant headwind in 2024. (reuters.com)
Disruptions in the Red Sea have led to longer shipping times, potentially affecting supply chain efficiency and operational costs. (reuters.com)
Smith & Nephew has experienced high executive turnover, with four CEOs in the past five years, which may indicate internal instability and affect strategic continuity. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Smith & Nephew News
AllArticlesVideos
Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland
GlobeNewsWire·2 months ago
Smith & Nephew shares jump 7% on better-than-expected quarterly growth
Proactive Investors·2 months ago
Smith & Nephew jumps as hip and knee replacements in demand
Proactive Investors·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SN) has a market cap of £9.4B as of June 20, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SN) stock is 30.87 as of June 20, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SN) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is £0.2858 and the yield is 2.66%. Smith & Nephew has a payout ratio of 79.37% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SN) dividend payment date is unconfirmed.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SN) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.